Exploring the Potential of Psychedelics in Brain Injury Recovery: A Thematic Analysis of Participant Narratives (2026)
Summary:
This exploratory qualitative study examined how individuals with traumatic brain injury (TBI) perceived the effects of psychedelic use on cognition, mental health, trauma recovery, and post-injury identity. Five adults with a history of TBI who had used psychedelics following injury participated in semi-structured interviews, analysed using reflexive thematic analysis. Three themes emerged: (1) trauma relief and mood stabilisation, involving reductions in anxiety, emotional reactivity, and trauma-related distress; (2) a temporary post-dose cognitive “lift”, particularly following macrodose experiences, characterised by perceived improvements in memory, clarity, coordination, and cognitive functioning; and (3) insight, acceptance, and self-compassion, reflecting increased self-understanding, identity reconstruction, and gentler relationships with the self after injury. Participants frequently interpreted post-dose cognitive changes as a temporary “neuroplastic window” potentially relevant to rehabilitation and recovery.
Psychedelics for the Management of Symptoms of Traumatic Brain Injury: Findings from the Global Psychedelic Survey (2026)
Summary:
This global survey study examined naturalistic psychedelic self-administration among individuals with traumatic brain injury (TBI) who reported using psychedelics with the intention of managing brain injury-related symptoms. Drawing from the Global Psychedelic Survey, researchers identified 145 respondents with traumatic brain injury who described using psychedelics outside formal medical or clinical settings for symptom relief. Participants reported targeting a broad range of cognitive, emotional, and somatic symptoms, including difficulties with memory, attention, mood, anxiety, fatigue, headaches, and sleep disturbance. Across substances, psilocybin emerged as both the most used and most frequently endorsed “most effective” psychedelic, followed by compounds including LSD, DMT/5-MeO-DMT, ketamine, and ibogaine. The study provides one of the largest snapshots to date of how people with brain injuries are already experimenting with psychedelics as self-directed symptom management tools.
Access Paper: https://pubmed.ncbi.nlm.nih.gov/41621525/
Psychedelics for Acquired Brain Injury: A Review of Molecular Mechanisms and Therapeutic Potential (2023/2024)
Summary:
This narrative review examines the therapeutic rationale for using psychedelics in acquired brain injury (ABI), including traumatic brain injury, concussion, stroke, and related neurological conditions. The authors explore how psychedelics may target core pathological processes common across ABI, including neuroinflammation, oxidative stress, disrupted neurotransmission, mitochondrial dysfunction, impaired neuroplasticity, and cellular degeneration. Rather than focusing primarily on psychiatric outcomes, the review emphasises molecular and neurobiological mechanisms relevant to neurological recovery and repair.
Access Paper: https://pubmed.ncbi.nlm.nih.gov/38177350/
Psychedelics for Brain Injury: A Mini-Review (2021)
Summary:
This narrative mini review examines the emerging scientific rationale for using psychedelics in brain injury and neurorehabilitation, with a particular focus on traumatic brain injury (TBI), stroke, reperfusion injury, and disorders of consciousness. Rather than concentrating on psychiatric applications, the paper reviews potential neurobiological mechanisms relevant to neurological recovery, including neuroinflammation modulation, hippocampal neurogenesis, structural neuroplasticity, and altered brain complexity/consciousnessdynamics. The authors discuss evidence from preclinical studies, case reports, and theoretical models involving compounds such as psilocybin, DMT, LSD, MDMA, ketamine, and related analogues, while highlighting proposed pathways involving 5-HT2A receptors,sigma-1 receptors, BDNF signalling, and network-level brain complexity.
Access Paper: https://pubmed.ncbi.nlm.nih.gov/34393973/
Psilocybin Restores Behaviour and 5-HT₂A Signalling While Reducing Microglial Density After Chronic Traumatic Brain Injury in Rats (2026)
Summary:
This preclinical study investigated whether a single dose of psilocybin could improve long-term outcomes following traumatic brain injury (TBI). Researchers induced severe TBI in rats and waited one year—representing the chronic stage of injury—before administering either psilocybin or saline. Compared with untreated animals, psilocybin-treated rats demonstrated improvements in sensorimotor performance and aspects of learning and memory. Positron emission tomography (PET) imaging showed that psilocybin restored reductions in 5-HT₂A receptor binding caused by traumatic brain injury, while histological analyses revealed reduced microglial density within the prefrontal cortex, suggesting a reduction in chronic neuroinflammation. Although conducted in an animal model, the findings provide important mechanistic evidence that psilocybin may influence multiple biological pathways implicated in persistent brain injury, including serotonergic signalling, neuroplasticity, and neuroimmune function. The authors conclude that these findings support further investigation of psychedelic therapies for chronic traumatic brain injury.
Access Paper:https://doi.org/10.1016/j.xcrm.2026.102867
The Potential Role of Psilocybin in Traumatic Brain Injury Recovery: A Narrative Review (2025)
Summary:
This narrative review explores psilocybin’s potential relevance to traumatic brain injury recovery by synthesising evidence across neurobiology, pharmacology, inflammation, and psychiatric outcomes. The paper discusses how psilocybin may influence pathways highly relevant to TBI pathology, including neuroplasticity, synaptogenesis, neurogenesis, inflammatory signalling, and serotonergic modulation. It reviews possible mechanisms involving BDNF, mTOR signalling, immediate early genes, and 5-HT2A receptor activation, while also considering psychiatric sequelae commonly associated with TBI such as depression, anxiety, PTSD, and cognitive dysfunction. The authors emphasise that evidence remains preliminary and largely indirect but argue that psilocybin represents a promising candidate deserving targeted investigation within neurorehabilitation and acquired brain injury research.
Access Paper: https://pmc.ncbi.nlm.nih.gov/articles/PMC12190232/
Improved Mental Health Outcomes and Normalised Spontaneous EEG Activity in Veterans Reporting a History of Traumatic Brain Injuries Following Participation in a Psilocybin Retreat (2025)
Summary:
This observational study examined veterans with histories of traumatic brain injury who attended structured psilocybin retreats in Jamaica. Participants showed substantial improvements in depression, anxiety, quality of life, reintegration difficulties, and post-concussion symptoms four weeks after retreat participation. EEG findings suggested reductions in abnormal slow-wave activity (delta/theta) alongside altered alpha and beta connectivity patterns, potentially reflecting improved emotional regulation and cognitive processing. Although limited by small sample size and lack of controls, the study provides early evidence supporting psilocybin’s potential relevance for neurorehabilitation and TBI populations.
Access Paper: https://pubmed.ncbi.nlm.nih.gov/40842948/
Clinical Improvement Following an Integrative Iboga Microdosing Protocol in Post-Concussive and Hypoxic Brain Injury Syndromes (2026)
Summary:
This naturalistic case series explored an integrative iboga microdosing protocol in three individuals with persistent neurological symptoms following traumatic brain injury (TBI) or hypoxic-ischemic brain injury (HIBI). Participants completed a six-week protocol using Tabernanthe iboga root bark microdosing (4-days-on / 3-days-off schedule) alongside weekly Accelerated Experiential Dynamic Psychotherapy (AEDP) and supportive nutraceutical care. Reported symptoms before treatment included brain fog, fatigue, migraines, headaches, disequilibrium, mood instability, sleep disturbance, and cognitive difficulties. All three participants showed reported clinical improvement, with two achieving complete symptom remission at longer-term follow-up and discontinuing symptomatic medications. The authors emphasise that findings are hypothesis-generating only and cannot establish causality due to the multimodal, uncontrolled design.
Access Paper: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1840956/abstract
Neurorestorative Properties of Ibogaine: Linking Multi-Receptor Affinities to Remyelination and Metabolic Restoration (2026)
Summary:
This perspective/review paper examines ibogaine’s potential neurorestorative mechanisms, focusing on how its complex pharmacology may support neuronal repair, remyelination, and metabolic recovery in disorders involving white matter dysfunction, including traumatic brain injury (TBI), multiple sclerosis (MS), and opioid use disorder. The authors propose that ibogaine’s actions across NMDA, kappa-opioid, sigma, serotonergic, and other receptor systems may reduce excitotoxicity, improve metabolic homeostasis, promote neuroplasticity, and facilitate myelin repair. The review discusses potential roles for BDNF, GDNF, mTOR signalling, oligodendrocyte activity, immunomodulation, and cerebral blood flow, while integrating preclinical findings, observational human studies, and emerging neuroimaging evidence. The authors argue that remyelination and white-matter repair may represent a central therapeutic mechanism underlying ibogaine’s reported effects across neurological and psychiatric conditions.
Magnesium–Ibogaine Therapy Effects on Cortical Oscillations and Neural Complexity in Veterans with Traumatic Brain Injury (2025)
Summary:
This prospective observational study investigated how magnesium–ibogaine therapy (MISTIC) affects brain electrophysiology in combat veterans with traumatic brain injury using resting-state EEG. Researchers measured neural activity before treatment, several days after treatment, and again at one-month follow-up. Following ibogaine therapy, participants demonstrated changes in cortical oscillatory dynamics, including increased slower-frequency activity (theta–alpha power) and reduced faster-frequency activity (beta–gamma power). The study also identified reductions in neural complexity and changes in oscillatory organisation that persisted at follow-up. Importantly, these neurophysiological changes correlated with improvements in executive functioning, PTSD symptoms, anxiety, and cognitiveinhibition, linking altered brain dynamics to clinical outcomes.
Magnesium–Ibogaine Therapy in Veterans with Traumatic Brain Injuries (2024)
Summary:
This prospective observational study examined magnesium–ibogaine therapy (MISTIC) in 30 US Special Operations veterans with predominantly mild traumatic brain injury (TBI) and histories of repeated blast/combat exposure. Participants received monitored ibogaine treatment combined with magnesium supplementation and supportive therapeutic activities. Researchers measured changes in disability, PTSD, depression, anxiety, suicidality, and cognitive performance immediately after treatment and at 1-month follow-up. The study reported large improvements in functional disability, PTSD symptoms, depression, anxiety, and cognitive performance, with benefits largely maintained at one month. No serious adverse events were observed under monitored administration conditions. The authors emphasise that findings are preliminary and require replication in controlled clinical trials.
Access Paper: https://pubmed.ncbi.nlm.nih.gov/38182784/